nL62541

ATN1-targeted antisense oligonucleotide · n-Lorem Foundation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for nL62541, covering 2026-04-07 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation [Phase 1, Phase 2]

See pricing